Skoči na glavni sadržaj

Izvorni znanstveni članak

https://doi.org/10.15836/ccar2024.156

Inequalities in mortality due to ischaemic heart disease among people over 65 years, 1990-2016

Noémi Németh orcid id orcid.org/0000-0002-0376-9478 ; Department for Health Insurance, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
Imre Boncz orcid id orcid.org/0000-0003-3699-6236 ; Department for Health Insurance, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
Diána Elmer orcid id orcid.org/0000-0001-7843-1001 ; Department for Health Insurance, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
Lilla Horváth orcid id orcid.org/0000-0002-2744-0669 ; Department for Health Insurance, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
Tímea Csákvári orcid id orcid.org/0000-0002-3339-4953 ; Department for Health Insurance, Faculty of Health Sciences, University of Pécs, Zalaegerszeg, Hungary
Dóra Endrei orcid id orcid.org/0000-0001-8979-1686 ; Department for Health Insurance, Faculty of Health Sciences, University of Pécs, Pécs, Hungary


Puni tekst: hrvatski pdf 1.659 Kb

str. 156-165

preuzimanja: 30

citiraj

Puni tekst: engleski pdf 1.659 Kb

str. 156-165

preuzimanja: 32

citiraj

Preuzmi JATS datoteku


Sažetak

SUMMARY
AimsIschaemic heart disease is the most common cause of death worldwide according to data of the World Health Organization. Our aim was to analyse national and international data regarding ischaemic heart disease mortality per region in the age group 65 years and above.
MethodsWe performed a retrospective, quantitative analysis on age-specific, ischaemic heart disease mortality between 1990-2016 per 100,000 population on data derived from the World Health Organisation, European Mortality Database on Western European (N=17), Eastern European (N=10) countries, and countries of the former Soviet Union (N=15). Descriptive statistics, time series analysis and Kruskal-Wallis test were performed.
ResultsAge-related, ischaemic heart disease mortality per 100,000 population was the lowest in Western European countries (males: 1990: 1391.00, 2016: 513.00; females: 1990: 746.91, 2016: 264.93), and the highest in former Soviet Union countries (males: 1990: 3133.51; 2016: 2204.41; females: 1990: 2257.45, 2016: 1566.44). Significant differences were found in age-specific, ischaemic heart disease mortality in both sexes between Eastern and Western European countries and former Soviet Union countries (1990, 2004, 2016: p<0.05). Between 1990-2016, age-specific, standardized ischaemic heart disease mortality showed the biggest decrease in Western European countries (males: -63.12%, females: -64.53%) followed by Eastern European (males: -29.93%, females: -31.50%) and former Soviet Union countries (males: -29.65%, females: -30.61%).
ConclusionsAge-specific, ischaemic heart disease mortality decreased in both sexes in all regions analysed. Hungary was found to have seen a decrease lower than the Eastern European average; ischaemic heart disease mortality decreased by 11.57% in males and 10.26% in females aged 65 and over between 1990-2016.

Ključne riječi

ischaemic heart disease; mortality; epidemiology

Hrčak ID:

314496

URI

https://hrcak.srce.hr/314496

Datum izdavanja:

8.2.2024.

Podaci na drugim jezicima: hrvatski

Posjeta: 142 *




Introduction

Cardiovascular diseases are leading causes of mortality and morbidity worldwide. Although there has been a decrease in age-standardised mortality rates in several regions of the world, the absolute number of deaths associated with CVDs has been increasing, mainly in middle-income and low-income countries. (1,2) Cardiovascular diseases are leading causes of death in Hungary followed by malignant cancers. (3-5) Diseases of the circulatory system accounted for 55% of mortality among females and 45%- among males in 2015 (6).

Our paper intends to analyse mortality data among people aged above 65 years due to ischaemic heart disease (IHD) within CVDs. According to World Health Organization (WHO) data, IHD is the most common cause of mortality registered globally. (6) Despite the fact that age-standardised mortality due to IHD has decreased in recent years, the associated disease burden has remained considerably high and has increased globally and in Hungary as well. (7-10) IHD is responsible for more than half of Disability-Adjusted Life Years (DALY) due to cardiovascular diseases. (6)

Mortality data due to IHD vary considerably per region. Data for different countries also vary markedly with time. (11) Nowadays, IHD has been increasingly affecting middle-aged populations of low- and middle-income countries, mainly due to changes in lifestyle, stress and other factors. (12) Although the health status of the population in Eastern Europe, including Hungary, has been improving, quality of life indicators have remained lower compared to Western European countries. (13,14) Societal, political and economic changes have negatively impacted health status in countries of the former Soviet Union. (11,15)

Our aim was to analyse and compare international and national mortality data associated with IHD above 65 years of age per region.

Data and methods

We performed a retrospective, quantitative analysis on age-specific, ischaemic heart disease mortality per 100,000 population among people aged 65 years and above. Our analysis focused on countries selected from the WHO European Region including the following Western European countries (N=17; Austria, Belgium, Denmark, Finland, France, Germany, Greece, the Netherlands, Ireland, Luxemburg, Norway, Italy, United Kingdom, Portugal, Sweden, Spain, Switzerland), Eastern European countries (N=10; Bulgaria, Bosnia-Herzegovina, Czechia, Croatia, Poland, Hungary, Romania, Serbia, Slovakia, Slovenia), and countries of the former Soviet Union (N=15; Azerbaijan, Estonia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Armenia, Tajikistan, Turkmenistan, Ukraine, Uzbekistan). Due to availability of data, we analysed the period between 1990 and 2016 with special focus on the years 1990, 2004 and 2016.

We investigated change through time in standardised mortality due to ischaemic heart disease and regional inequalities among the above groups of countries.

Data were derived from the World Health Organisation, European Mortality Database on the following indicator: „SDR, ischaemic heart disease, 65+, per 100 000” (International classification of diseases 10: I20-I25)”. Data for the given countries originate from national registries.

Besides descriptive statistics (mean confidence interval; distribution: standard deviation, SD) time-series analysis, and mathematical statistics tests (Kruskal-Wallis test) were performed at 95% confidence interval (CI) (p<0.05). Upon testing preconditions the requirements for normality testing (Shapiro-Wilk test) were not fulfilled, thus we decided to perform a Kruskal-Wallis, non-parametric test.

MS Excel 2007 SPSS 22.0 programmes were used for analyses.

Results

In 1990, age-specific mortality per 100,000 population among males above age 65 years was an average 2.2 times higher in post-Soviet countries (3133.51; SD=499.33; min=2371.15: Tajikistan; max=4125.20: Estonia) than in Western European countries (1391.00; SD=600.15; min=604.42: France; max=2379.13: Finland). Age-specific mortality due to IHD among males was minimally higher in Eastern Europe (1418.98; SD=765.89; min=599.71: Croatia; max=2834.57: Czechia) than in Western Europe in 1990. In 2004, mortality caused by IHD among males older than 65 years was an average 3.7 times higher in post-Soviet states (3201.42; SD=840.57; min=2063.90: Tajikistan; max=4947.58: Moldova) and 1.7 times higher in Eastern European countries (1491.38; SD=570.85; min=771.77: Slovenia; max=2575.41: Slovakia) compared to Western European countries (869.17; SD=289.32; min=441.83: France; max=1506.00: Finland). In 2016, age-specific mortality per 100,000 population was 4.3 times higher among males in post-Soviet countries (2204.41; SD=908.77; min.=702.68: Georgia; max.=3513.83: Kyrgyzstan), and 1.9 times higher in Eastern European countries (994.27; SD=402.38; min.=511.85: Slovenia; max.=1695.57: Hungary) than in Western European countries (513.00; SD=196.87; min.=297.20: Netherlands; max.=987.18: Finland). Significant differences were found with regard to mortality due to IHD among males between Eastern-, Western European countries and countries of the former Soviet Union (1990; 2004; 2016: p<0.05). (Figure 1)

FIGURE 1 Standardised mortality due to ischaemic heart disease among males aged above 65 years in1990, 2004 and 2016 (95% CI) [*: p < 0.05, Kruskal-Wallis test]. WE = Western European countries; EE = Eastern European countries; FSU = former Soviet Union countries
CC202419_3-4_156-65-f1

In 1990, Age-specific mortality among females was three times higher on average in post-Soviet states (2257.45 SD=375.40; min=1623.20: Kyrgyzstan; max=2821.50: Turkmenistan), 1.27 times higher in Eastern European countries (948.61; SD=550.69; min=279.80:Croatia; max=1723.63: Czechia) compared to Western European countries (746.91; SD=320.64; min=320.38: France; max=1289.87: Finland). In 2004, age-specific mortality among females was 4.53 times higher in post-Soviet states (2202.12; SD=666.07; min=1352.07: Tajikistan; max=3819.84: Moldova), and 2.15 times higher in Eastern Europe (1045.03; SD= 436.95; min=476.90: Slovenia; max=1416.01: Hungary) than in Western Europe (486.30; SD=176.98; min=205.76: France; max=812.92: Finland). In 2016, standardised mortality rates among females were 5.91 times higher in post-Soviet states (1566.44; SD=790.25; min=455.37: Georgia; max=2766.81: Kyrgyzstan), 2.45 times higher in Eastern Europe (649.77; SD=295.80; min=233.09: Slovenia; max=1118.89: Hungary) than in Western Europe (264.93; SD=105.98; min=148.14: Netherlands; max=482.83: Austria). Significant differences were found with regard to mortality due to IHD among females above age 65 years between Eastern-, Western European countries and countries of the former Soviet Union (1990; 2004; 2016: p<0.05). (Figure 2)

FIGURE 2 Standardised mortality due to ischaemic heart disease among females aged above 65 years in 1990, 2004 and 2016 (95% CI) [*: p < 0.05, Kruskal-Wallis test]. WE = Western European countries; EE = Eastern European countries; FSU = former Soviet Union countries
CC202419_3-4_156-65-f2

Between 1990 and 2016 age-standardised mortality due to IHD among males and females decreased most markedly in Western European countries (males: -63.12%; females: -64.53%) followed by the Eastern European countries we examined (males: -29.93%, females: -31.50%), and countries of the former Soviet Union (males: -29.65%; females: -30.61). Regarding Western European countries, age-specific mortality due to IHD showed a continuous decline with minimal fluctuation from 1990 until the end of the period under examination. In the case of Eastern European countries, we found the highest rates in both sexes in 1997 and saw an increase between 1990 and 1997 (males: +36.27%; females: +40.65%), and a continuous decrease between 1997 and 2016 with minor fluctuations (males: -48.58%; females: -51.30%). In post-Soviet countries, age-specific mortality due to IHD was the highest in 1996 among females, and in 2003 among males. Among women, standardised mortality increased by 11.58% in total between 1990 and 1996 and showed an overall decrease with minor fluctuations between 1996 and 2016 (-37.81%). With regard to standardised mortality in males, the period between 1990 and 2003 witnessed a 12.5% increase, followed by a decrease between 2003 and 2016 (-37.46%) with slight fluctuations (Figure 3).

FIGURE 3 Age-standardised mortality due to ischaemic heart disease among people aged above 65 years between 1990 and 2016.
CC202419_3-4_156-65-f3

Figure 4 shows percentage change in age-specific mortality due to IHD in males. Azerbaijan, Estonia, Belarus, France, Ireland, Kazakhstan, Russia, Spain, Serbia, Slovakia, Tajikistan, Turkmenistan and Ukraine are not represented due to lack of data. During the entire period investigated age-specific mortality among males decreased on average by 39.91% in each country. 20 countries were found to have reported better than average data and in 10 countries decrease was smaller than average. Out of the latter group, six were post-Soviet and four were Eastern European countries. Mortality due to IHD among males over 65 years of age showed a decrease in all countries examined during the period between 1990 and 2016 except for Croatia (+97.89%), Kyrgyzstan (+46.46%), Bosnia-Herzegovina (+14.61%) and Moldova (+1.04%). Compared to the base year, by 2016, most favourable changes were registered in Denmark (-82.02%), Georgia (-78.19%) and the Netherlands (-77.04%) among males. The smallest change was witnessed in Hungary (-11.57%) followed by Russia (-12.69%) and Poland (-27.39%) among males above age 65 years.

FIGURE 4 Changes in standardised mortality due to ischaemic heart disease among males aged above 65 years per country between 1990 and 2016.
CC202419_3-4_156-65-f4

With regard to females, similar to males, we intended to present percentage change in age-specific, mortality due to IHD for countries selected for examination. Some countries are missing from the graph due to lack of available data (Azerbaijan, Belarus, France, Ireland, Kazakhstan, Russia, Spain, Serbia, Slovakia, Tajikistan, Turkmenistan, Ukraine). Based on data available, mortality rates due to IHD among females aged above 65 years improved with 37.68% on average in each country. 21 countries witnessed better than average and nine countries less than average change. Out of the latter group, five were Eastern European countries and four were former Soviet countries.

Among females age above 65 years, mortality due to IHD decreased between 1990 and 2016 except for Croatia (+202.27%), Kyrgyzstan (+70.45%) and Bosnia-Herzegovina (+38.79%). Compared to the base year, the most favourable change by 2016 was found to have been reported Denmark (-83.82%) followed by Georgia (-81.15%) and the Netherlands (-76.81%) among women. Mortality due to IHD decreased the least in Moldova (-2.24%), Hungary (-10.26%), and Poland (-13.62%) among females older than 65 years. (Figure 5)

FIGURE 5 Changes in standardised mortality due to ischaemic heart disease among females aged above 65 years per country between 1990 and 2016.
CC202419_3-4_156-65-f5

Discussion

In our study, we examined mortality due to IHD in the population aged above 65 years in Eastern-, Western European countries and post-Soviet states within the WHO European Region.

The past 25 years have seen a decrease in standardised mortality due to IHD worldwide nonetheless, marked regional inequalities have persisted. High-income countries have reported the most positive change (2,12,16). According to our analysis, age-specific mortality due to IHD in the population older than 65 years was the lowest in Western European countries in both males and females and the highest in countries of the former Soviet Union. Nevertheless, upon comparing Eastern European and post-Soviet countries only minimal change was observable between 1990 and 2016 with regard to average standardised mortality rates. During the period analysed, male mortality rates increased in two Eastern European countries (Croatia, Bosnia-Herzegovina) and two former Soviet states (Kyrgyzstan, Moldova). Regarding females, two Eastern European countries (Croatia, Bosnia-Herzegovina) and one post-Soviet country (Kyrgyzstan) were found to have had an increase in age-standardised mortality. We suspect that the sharp increase in this respect, as found in Croatia, may have been due to variations in fulfilling reporting obligations. The above is supported by the fact that mortality due to IHD reportedly dropped considerably between 1995 and 2011 in Croatia (17). Unfavourable data with regard to Bosnia-Herzegovina have also been published by other researchers. Cardiovascular risk factors, the effects of stress and the economic situation of the country are suspected to be in the background of high mortality rates. (18) The increase in Kyrgyzstan as described above is in line with other findings (11).

During the period between 1990 and 2016, mortality due to IHD among people aged above 65 years decreased less than the Eastern European average in Hungary; decrease among males was 11.57% and 10.26% among females.

Comparing data for Hungary with those of Visegrad countries, we found that in 1990 mortality due to IHD among people aged older than 65 years higher in Czechia than in Hungary. In 2016, age-specific mortality was higher in Hungary than in Czechia. Our analysis revealed that during the period between 1990 and 2016, mortality rates decreased much more markedly in both sexes in Czechia than in our country. In Poland, age-specific mortality due to ischaemic heart disease was considerably lower both in 1990 and in 2016 than in Hungary. There were no data available on Slovakia for the years 1990 and 2016. Between 1990 and 2016, in the years with available data, age-specific mortality due to ischaemic heart disease in the population above 65 years was higher in both sexes in Slovakia than in our country. Regarding risk factor prevalence, in Visegrad countries, according to WHO data, in 2015, Hungary and Poland nearly exactly the same prevalence rates of smoking in males and a slightly higher prevalence in females, in Hungary. In the Czech Republic, the prevalence of smoking was higher in both sexes than in our country. With regard to Slovakia, smoking prevalence was higher among men compared to Hungary (19). The prevalence of obesity was higher in both sexes in Hungary than in Poland or Slovakia. In Czechia it was higher among women than in our country. (20) Regarding statin adherence, we can hereby present some Hungarian research data: according to Jánosi et al. 54.4% of patients showed good statin adherence one year after suffering a myocardial infarction (21). J. Tomcsányi investigated statin adherence among patients having had an acute myocardial infarction and found an average 70% adherence rate (22). Earlier findings published by Kiss et al. revealed lower persistence with regard to statin therapy in comparison with other countries (23).

The results of our analyses may have been distorted by the fact that 12 countries, including Belarus and Ukraine, could not be included in the analysis comparing countries regarding the years 1990 and 2016 due to lack of statistical data.

Mortality indices are greatly impacted by societal-, political- and economic stress. Lower socio-economic status correlates with unfavourable health status indices. (24,25) After 1990, Eastern European countries and post-Soviet states have witnessed significant societal changes. After 2004 the majority of Eastern European countries joined the European Union. (26,27)

Increasing in life expectancy, the aging of the society, the inadequate adherence to evidence-based guidelines, issues arising during the implementation and facilitation of preventive measures and the COVID epidemic have all contributed to the very high disease burden associated with cardiovascular diseases (28-30). The morbidity and mortality associated with cardiovascular diseases depend on the prevalence of risk factors that play a role in their development. Regarding DALY, smoking has continued to be the most important risk factor, smoking cessation programmes play a crucial role (31-33). In 2015, the prevalence of smoking in Hungary among males aged older than 15 years was 32%, and 24.8% among females according to WHO data (19). Concerning the development of IHD, obesity is also one of the main risk factors (34-36). In 1990, the prevalence of obesity in Hungary was 16.9%, in 2016 it was 26.4% in the population above age 18. (20) Rising incomes result in higher food consumption levels among people with lower incomes as well resulting in higher prevalence of obesity in these groups and consequently, a higher risk of CVDs. Regarding the prevention of obesity, population-level strategies e.g. the introduction of the public health product tax and food-health regulations concerning mass catering may prove beneficial. (37,38)

Besides a bigger emphasis devoted to primary prevention, the favourable change in mortality statistics are also due to development of the healthcare system including advances in therapeutic and diagnostic modalities and the establishment of cardiac-catheter centres. (39-41) Between 1993 and 2007, the mortality rates associated with acute myocardial infarction decreased from 15,000 to 8,400. In 2007, mortality due to acute myocardial infarction accounted for 47% of all-cause mortality in 1993 per 100,000 population. Improvement in this respect is due to highly effective pharmacoceuticals in addition to advancement in medical intervention and emergency care therapies. (42) Further measures are necessary to improve mortality statistics targeting the reduction of cardiovascular risk factors and the promotion and facilitation of healthy lifestyle. (12,43-45) The 2021 Guideline of The European Society of Cardiology includes the most up-to-date protocols with regard to cardiovascular risk assessment which contain details on individual risk reduction strategies and therapeutic targets. The guideline designates the promotion and facilitation of a healthy lifestyle to be followed lifelong as the most important preventive factor. The guideline also emphasizes the assessment of psycho-social stress, the importance of anti-thrombocyte therapy, disease-specific interventions and introduces the benefits of life-long risk assessment. The prevention guideline mentions public health policy, representation, the application of societal risk reduction strategies and the introduction of measures to reduce air-pollution among methods targeting societal risk reduction. (44)

The introduction of regulations regarding the lower taxes on healthy foods has been an important element in health-policy decision making.

Our research has some limitations which may have influenced our findings including lack of available data from the WHO database (lack of mortality data on IHD which could be expressed in absolute numbers, occasional lack of standardised mortality data), differences in mortality statistics used by the different countries, variations in reporting obligations and differences in data validation protocols. The comparison of our results with findings of other research is limited due to differences in geographical categorisation of the countries. Due to considerable lack of available data we could not extend the timeline of our research to include further years.

Acknowledgement, funding

The research was financed by the Thematic Excellence Program 2021 Health Sub-programme of the Ministry for Innovation and Technology in Hungary, within the framework of the EGA-10 project of the University of Pécs.

LITERATURE

1 

Balogh S, Papp R, Jozan P, Csaszar A. Continued improvement of cardiovascular mortality in Hungary--impact of increased cardio-metabolic prescriptions. BMC Public Health. 2010 July 15;10:422. https://doi.org/10.1186/1471-2458-10-422 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/20633257

2 

Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. Circ Res. 2017 September 1;121(6):677–94. https://doi.org/10.1161/CIRCRESAHA.117.308903 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/28860318

3 

Farkas K. Perifériás érbetegségek nőkben. In: A nők egészségéről és betegségeiről Helyzetkép a XXI. század elején (Ed. Masszi G.) 2019, Budapest, Harc a női szívekért alapítvány

4 

Horváth L, Németh N, Fehér G, Kívés Z, Endrei D, Boncz I. Epidemiology of Peripheral Artery Disease: Narrative Review. Life (Basel). 2022 July 12;12(7):1041. https://doi.org/10.3390/life12071041 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/35888129

5 

Kriszbacher I, Boncz I, Koppán M, Bódis J. Seasonal variations in the occurrence of acute myocardial infarction in Hungary between 2000 and 2004. Int J Cardiol. 2008 September 26;129(2):251–4. https://doi.org/10.1016/j.ijcard.2007.07.095 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/18023894

6 

Népegészségügyi Képző- és Kutatóhelyek Országos Egyesülete (NKE). Nemzeti Népegészségügyi Program (NNP) 2018–2030 szakpolitikai stratégia tervezete. Szív-érrendszeri betegségek megelőzése. Nepegeszseguegy. 2019;97(1):46–9.

7 

Moran AE, Tzong KY, Forouzanfar MH, Rothy GA, Mensah GA, Ezzati M, et al. Variations in ischemic heart disease burden by age, country, and income: the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Glob Heart. 2014 March;9(1):91–9. https://doi.org/10.1016/j.gheart.2013.12.007 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24977114

8 

Dai H, Much AA, Maor E, Asher E, Younis A, Xu Y, et al. Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990-2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2022 January 5;8(1):50–60. https://doi.org/10.1093/ehjqcco/qcaa076 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/33017008

9 

Németh N, Endrei D, Elmer D, Csákvári T, Horváth L, Kajos LF, et al. A heveny szívinfarktus okozta országos epidemiológiai és egészségbiztosítási betegségteher Magyarországon [Epidemiological disease burden and annual health insurance treatment cost of acute myocardial infarction in Hungary]. Orv Hetil. 2021 Mar 28;162(162 Suppl 1):6-13. Hungarian. https://doi.org/10.1556/650.2021.32153 https://doi.org/10.1556/650.2021.32153

10 

Németh N, Endrei D, Horváth L, Elmer D, Csákvári T, Pónusz R, et al. A cerebrovascularis betegségekből eredő, idő előtti halálozás egyenlőtlenségei Európában 1990 és 2014 között [Inequalities in premature mortality due to cerebrovascular disease in Europe between 1990 and 2014]. Orv Hetil. 2021 Jan 24;162(4):144-152. Hungarian. https://doi.org/10.1556/650.2021.31980 https://doi.org/10.1556/650.2021.31980

11 

Murphy A, Johnson CO, Roth GA, Forouzanfar MH, Naghavi M, Ng M, et al. Ischaemic heart disease in the former Soviet Union 1990-2015 according to the Global Burden of Disease 2015 Study. Heart. 2018 January;104(1):58–66. https://doi.org/10.1136/heartjnl-2016-311142 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/28883037

12 

Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation. 2014 April 8;129(14):1483–92. https://doi.org/10.1161/CIRCULATIONAHA.113.004042 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24573352

13 

Meier T, Gräfe K, Senn F, Sur P, Stangl GI, Dawczynski C, et al. Cardiovascular mortality attributable to dietary risk factors in 51 countries in the WHO European Region from 1990 to 2016: a systematic analysis of the Global Burden of Disease Study. Eur J Epidemiol. 2019 January;34(1):37–55. https://doi.org/10.1007/s10654-018-0473-x PubMed: http://www.ncbi.nlm.nih.gov/pubmed/30547256

14 

Boncz I, Vajda R, Ágoston I, Endrei D, Sebestyén A. Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010. Eur J Health Econ. 2014 May;15 Suppl 1:S137–41. https://doi.org/10.1007/s10198-014-0602-8 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24832844

15 

Boncz I, Sebestyén A. Economy and mortality in Eastern and Western Europe between 1945 and 1990: the largest medical trial of history. Int J Epidemiol. 2006 June;35(3):796–7. https://doi.org/10.1093/ije/dyl075 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/16638815

16 

Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014 April 8;129(14):1493–501. https://doi.org/10.1161/CIRCULATIONAHA.113.004046 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24573351

17 

Kralj V, Šekerija M. Ischemic heart disease mortality trends in Croatia between 1995 and 2011: a joinpoint regression analyisis. Cardiol Croat. 2014;9(5-6):161. https://doi.org/10.15836/ccar.2014.161

18 

Masic I, Dilic M, Raljevic E, Vulic D, Mott D. Trends in cardiovascular diseases in Bosnia and Herzegovina and perspectives with heartscore programme. Med Arh. 2010;64(5):260–3. https://doi.org/10.5455/medarh.2010.64.260-263 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/21287948

19 

World Health Organization. Tobacco control policies and interventions, 2017. Monitoring tobacco use and prevention policies. WHO, Geneva, ISBN 978-92-4-151282-4.http://gamapserver.who.int/gho/interactive_charts/tobacco/use/atlas.html [2022.10.04]

20 

World Health Organization. Prevalence of obesity among adults, ages 18+, 1975-2016.http://gamapserver.who.int/gho/interactive_charts/ncd/risk_factors/obesity/atlas.html [2022.10.04]

21 

Jánosi A, Ofner P, Kiss Z, Kiss L, Kiss RG, Dinnyés J, et al. Szívinfarktust túlélt betegek terápiahűsége a másodlagos megelőzés szempontjából fontos gyógyszeres kezelésekhez [Adherence to medication after myocardial infarction and its impact on outcome: a registry-based analysis from the Hungarian Myocardial Infarction Registry]. Orv Hetil. 2017 Jul;158(27):1051-1057. Hungarian. https://doi.org/10.1556/650.2017.30795 https://doi.org/10.1556/650.2017.30795

22 

Tomcsányi J. Statin gyógyszerszedési gyakorlat myocardialis infarctus után Magyarországon [Adherence to statins in patients with myocardial infarction in Hungary]. Orv Hetil. 2017 Mar;158(12):443-446. Hungarian. https://doi.org/10.1556/650.2017.30687 https://doi.org/10.1556/650.2017.30687

23 

Kiss Z, Nagy L, Reiber I, Paragh G, Molnar MP, Rokszin G, et al. Persistence with statin therapy in Hungary. Arch Med Sci. 2013 June 20;9(3):409–17. https://doi.org/10.5114/aoms.2013.35327 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/23847660

24 

Carlson P. The European health divide: a matter of financial or social capital? Soc Sci Med. 2004 November;59(9):1985–92. https://doi.org/10.1016/j.socscimed.2004.03.003 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/15312932

25 

Bodis J, Boncz I, Kriszbacher I. Permanent stress may be the trigger of an acute myocardial infarction on the first work-day of the week. Int J Cardiol. 2010 October 29;144(3):423–5. https://doi.org/10.1016/j.ijcard.2009.03.051 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/19345426

26 

Boncz I, Nagy J, Sebestyén A, Korösi L. Financing of health care services in Hungary. Eur J Health Econ. 2004 October;5(3):252–8. https://doi.org/10.1007/s10198-004-0228-3 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/15714346

27 

Boncz I, Sebestyén A. Financial deficits in the health services of the UK and Hungary. Lancet. 2006 September 9;368(9539):917–8. https://doi.org/10.1016/S0140-6736(06)69369-0 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/16962878

28 

Van Camp G. Cardiovascular disease prevention. Acta Clin Belg. 2014 December;69(6):407–11. https://doi.org/10.1179/2295333714Y.0000000069 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/25176558

29 

Fekete M, Fehér Á, Varga JT. A szív- és érrendszeri egészség előmozdítása, stratégiák és lehetőségek az egészségfejlesztésben. MD Prevenció. 2022;1:25–8.

30 

Pina A, Castelletti S. COVID-19 and Cardiovascular Disease: a Global Perspective. Curr Cardiol Rep. 2021 August 19;23(10):135. https://doi.org/10.1007/s11886-021-01566-4 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/34410538

31 

Sipos V, Pálinkás A, Kovács N, Csenteri KO, Vincze F, Szőllősi JG, et al. Smoking cessation support for regular smokers in Hungarian primary care: a nationwide representative cross-sectional study. BMJ Open. 2018 February 3;8(2):e018932. https://doi.org/10.1136/bmjopen-2017-018932 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/29431134

32 

Cziráki A A dohányzás, mint kardiovaszkuláris/cerebrovaszkuláris rizikófaktor, a nikotin káros hatásai. Háziorvos továbbképző szemle 2007; 12(4): 287-291.

33 

Fényes M, Cselkó Zs. Terápiás lehetőségek alkalmazása a dohányzók leszokásának segítésére a kardiológiai gyakorlatban. Cardiol Hung (Nyomt). 2021;51:348–53. https://doi.org/10.26430/CHUNGARICA.2021.51.5.348

34 

Jakab AE, Illyés M, Cziráki A, et al. A túlsúly és elhízás előfordulási gyakorisága Szolnokon 3-18 éves populációban. Gyermekgyógyászat: gyermek- és ifjúság-egészségügyi szaklap 2018; 69(3): 157-162.

35 

Wang W, Hu M, Liu H, Zhang X, Li H, Zhou F, et al. Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell Metab. 2021 October 5;33(10):1943–1956.e2. https://doi.org/10.1016/j.cmet.2021.08.005 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/34478633

36 

Cybulska B, Kłosiewicz-Latoszek L. Landmark studies in coronary heart disease epidemiology. The Framingham Heart Study after 70 years and the Seven Countries Study after 60 years. Kardiol Pol. 2019;77(2):173–80. https://doi.org/10.5603/KP.a2019.0017 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/30828782

37 

Tóth K, Sándor B Kardiológia népegészségügyi szemmel. IME 2018; XVII; 7: 26-29.

38 

Pálfi A, Szekeres Zs, Sándor B, et al. Az elhízás és a COVID-19-infekció. Cardiol Hung (Nyomt). 2021;51:336–41. https://doi.org/10.26430/CHUNGARICA.2021.51.5.336

39 

Becker D, Skoda R, Bokor L, et al. A hazai szívinfarktus-ellátás eredményét befolyásoló tényezők elemzése. LAM. 2020;30:383–90.

40 

Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality From Ischemic Heart Disease. Circ Cardiovasc Qual Outcomes. 2019 June;12(6):e005375. https://doi.org/10.1161/CIRCOUTCOMES.118.005375 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/31163980

41 

Jánosi A, Ferenci T, Komócsi A, Andréka P. A kórelőzményben szereplő revascularisatiós műtét rövid és hosszú távú prognosztikai jelentősége szívinfarktus miatt kezelt betegekben [Short- and long-term prognostic significance of previous recanalization interventions in patients treated for myocardial infarction]. Orv Hetil. 2021 Jan 31;162(5):177-184. Hungarian. https://doi.org/10.1556/650.2021.31988 https://doi.org/10.1556/650.2021.31988

42 

Józan P. Csökkenő kardiovaszkuláris mortalitás, javuló életkilátások, új epidemiológiai korszak kezdete Magyarországon. IME. 2009;8:21–5.

43 

Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014 March 15;383(9921):999–1008. https://doi.org/10.1016/S0140-6736(13)61752-3 PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24084292

44 

Szabados E, Sándor B, Pálfi A. 2021. évi ESC-irányelvek a szív- és érrendszeri betegségek megelőzéséről a klinikai gyakorlatban. Cardiol Hung (Nyomt). 2022;52:60–72. https://doi.org/10.26430/CHUNGARICA.2022.52.5.60

45 

Márk L. Beke Sz, Vitrai J Gondolatok a kardiovaszkuláris prevencióról, a populációs és a nagy kockázatra szabott klinikai stratégia hatékonyságáról. Cardiol Hung (Nyomt). 2022;52:73–6. https://doi.org/10.26430/CHUNGARICA.2022.52.5.73


This display is generated from NISO JATS XML with jats-html.xsl. The XSLT engine is libxslt.